<DOC>
	<DOCNO>NCT01335607</DOCNO>
	<brief_summary>The purpose study : - Assess relative bioavailability 2 oral formulation samatasvir ( capsule tablet prototype test formulation ) - Compare amount study drug blood take either capsule form drug tablet form drug fasting . - Determine amount study drug blood eat meal . - Evaluate safety tablet form samatasvir healthy people .</brief_summary>
	<brief_title>A Open-label Study Evaluate Relative Bioavailability Samatasvir ( IDX184 ) Food Effect Healthy Male Participants ( MK-2355-006 )</brief_title>
	<detailed_description>Each participant receive formulation crossover design . Part A Periods 1 2 : Participants receive either samatasvir capsule tablet accord randomization fasting condition Days 1 8 . Part A Period 3 : All participant receive samatasvir tablet fed conditons Day 15 . Each dose separate 7-day wash-out period . Part B : All participant receive samatasvir capsule feed conditons Day 1 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Must healthy male body mass index ( BMI ) 18 35 kg/m Must agree use acceptable doublebarrier method birth control . Must provide write informed consent study fully explain . History clinically significant disease , determine investigator . Safety laboratory abnormality screen clinically significant . Positive screen test hepatitis B virus , hepatitis C virus human immunodeficiency virus ( HIV ) . Use chronic prescription medication within 3 month , acute prescription medication within 14 day , systemic overthecounter ( OTC ) medication within 7 day start study . Current abuse alcohol illicit drug , history alcohol illicit drug abuse within precede two year .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>